Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
  • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
  • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
  • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
  • C07C227/02—Formation of carboxyl groups in compounds containing amino groups, e.g. by oxidation of amino alcohols
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C247/00—Compounds containing azido groups
  • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
  • C07C247/08—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated
  • C07C247/10—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C253/00—Preparation of carboxylic acid nitriles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C255/00—Carboxylic acid nitriles
  • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
  • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
  • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C255/00—Carboxylic acid nitriles
  • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
  • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
  • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
  • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
  • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
  • C07C271/06—Esters of carbamic acids
  • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
  • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
  • C07C29/09—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis
  • C07C29/10—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of ethers, including cyclic ethers, e.g. oxiranes
  • C07C29/103—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of ethers, including cyclic ethers, e.g. oxiranes of cyclic ethers
  • C07C29/106—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of ethers, including cyclic ethers, e.g. oxiranes of cyclic ethers of oxiranes
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
  • C07C29/36—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
  • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
  • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
  • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
  • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
  • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
  • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
  • C07D203/10—Radicals substituted by singly bound oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
  • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
  • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
  • C07D203/16—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms
  • C07D203/18—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms by carboxylic acids, or by sulfur or nitrogen analogues thereof
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• 2008-0094604 discloses that when triazolo piperazine part of sitagliptin is substituted with piperazinone containing hetero atom, it has an excellent DPP-IV inhibition activity, and also a significantly improved bioavailability as compared to that of the conventional DPP-IV inhibitor; and provides a heterocyclic compound containing new beta-amino group represented by the following Chemical Formula 1, or pharmaceutically acceptable salt thereof, a method for manufacturing the same, and a, pharmaceutical composition, which contains the same as an effective component, for preventing and treating diabetes or obesity.
• Korean Patent Publication No. 2008-0094604 discloses a method for manufacturing heterocyclic compound represented by Chemical Formula 1 with beta-amino group, the method comprising I) preparing a compound represented by Chemical Formula 4 bonded with peptide bond by reacting a compound with beta-amino group represented by Chemical Formula 2 and a substituted heterocyclic compound represented by Chemical Formula 3 using 1-hydroxybenzotriazol (HOBT), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), and tertiary amine; and II) reacting the compound represented by Chemical Formula 4 under an acid condition:
• HOBT 1-hydroxybenzotriazol
• EDC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
• tertiary amine tertiary amine
• the compound with beta-amino group represented by Chemical Formula 2 in the above Reaction Formula A may be used for manufacturing various DPP-IV inhibitors as disclosed in International Laying-Open Gazettes WO03/000181, WO03/004498, WO03/082817, WO04/007468, WO04/032836, WO05/011581, WO06/097175, WO07/077508, WO07/063928, WO08/028662, WO08/087560, and the like, besides the production of DPP-IV inhibitor represented by the above Chemical Formula 1, and may be produced through various methods.
• ester compound is obtained through an amine-protecting reaction after reacting (2S)-(+)-2,5-dihydro-3,6-dimethoxy -2-isopropylpirazine with 2,4,5-trifluorobenzyl bromide and acid-treating.
• the ester compound may be again hydrolyzed to obtain 3-(2,4,5-trifluorophenyl)-2-aminopropionic acid; then diazoketone may be formed by using isobutyl chloroformate, tertiary amine such as triethyl amine or diisopropylethyl amine, and diazomethane; and the compound represented by Chemical Formula 2 may be produced by reacting the diazoketone with silver benzoate.
• the reaction as mentioned above has problems that it should be performed at low temperature ( ⁇ 78° C.), or should use an expensive alpha-amino acid and highly risky diazomethane.
• 2,4,5-trifluorophenyl acetic acid is activated using 1,1′-carbonylimidazole, and then reacted with mono-methyl potassium malonate to produce beta-keto ester compound.
• the beta-keto ester compound is reacted with ammonium acetate and ammonium aqueous solution to produce enamine ester, and the ester compound is then reacted with chloro(1,5-cyclooctadiene)rhodium (I) dimer and chiral ferroceny ligand I through a high-pressure hydrogen reaction to produce the compound that is a beta-amino ester having chiral primary amine only.
• the compound may be hydrolyzed to produce the compound represented by Chemical
• the corresponding compound is reacted with (s)-BINAP-RuC1 2 that is a reduction reagent with enantioselectivity through a hydrogen reaction to produce a compound with (S)-coordination, and then the resulting compound is again hydrolyzed and then is coupling-reacted with O-benzylhydroxyamine to produce an intermediate.
• the intermediate produced as mentioned above may be subjected to a ring condensation reaction in the presence of triphenylphosphine and diisopropylazodicarboxylate and treated with lithium hydroxide aqueous solution to produce the compound represented by Chemical Formula 2 with (R)-coordination also in which an amine group is protected with O-benzyl.
• the above method has a problem that an overall process is long and tedious so that the yield of reaction is low and the reaction should be performed for a long period.
• the conventionally known method for manufacturing the compound represented by Chemical Formula 2 has several problems such as use of an expensive reagent, long synthesizing time, and low yield, and thus it is not sufficient for a commercial mass-production.
• the compound represented by Chemical Formula 3 may be produced by using the following Reaction Formula as disclosed in Korean Patent Publication No. 2008-0094604:
• D-serine methyl ester compound which is a starting material, is substituted with trityl chloride; then hydroxyl group is again substituted with mesyl group, and then refluxed to convert to aziridine compound.
• the trityl group is removed from the aziridine compound by using trifluoroacetic acid; then the aziridine compound is protected with benzyloxycarbonyl (Cbz), and then is reacted with t-buthanol; and Cbz is de-protected to obtain methyl 2-amino-3-substituted carbonate.
• Cbz benzyloxycarbonyl
• the intermediate may be produced by using the compound produced by protecting the secondary amine of the compound produced through reacting N-butyloxycarbonyl-2-amino acetaldehyde with a reduction reagent (sodiumcyanoborohydride, sodiumtriacetoxyborohydride, sodiumborohydride, and the like) and the compound, of which secondary amine is protected with benzyloxycarbonyl (Cbz), and the compound of which butyloxycarbonyl (Boc) is de-protected.
• a reduction reagent sodiumcyanoborohydride, sodiumtriacetoxyborohydride, sodiumborohydride, and the like
• the compound produced as mentioned above is subjected to a cyclization with trimethyl aluminum (or diisopropylethylamine/ethanol, sodium hydrogen carbonate/methanol, and the like) to de-protect Cbz so that the compound represented by Chemical Formula 3 may be obtained.
• the above method has a problem that it also uses an expensive reagent, the time for synthesizing is long, and the yield is low so that it is not suitable for a commercial mass-production.
• the present inventors completed the present invention by confirming that the compound represented by Chemical Formula 1 can be economically produced with high yield by using the new method for manufacturing the compounds represented by Chemical Formula 2 and Chemical Formula 3 during the study for a manufacturing method suitable for a commercial mass-production, in which the method uses cheaper reagents; is an economical method; and improves a yield.
• One object of the present invention is to provide a method for manufacturing a useful compound as an intermediate for manufacturing dipeptidyl peptidase-IV inhibitor.
• Another object of the present invention is to provide an improved method for manufacturing dipeptidyl peptidase-IV inhibitor.
• the present invention provides a new method for manufacturing an intermediate of dipeptidyl peptidase-IV inhibitor.
• the present invention also provides an improved method for manufacturing dipeptidyl peptidase-IV inhibitor.
• the present invention can be useful for mass-production through reducing the production cost by using cheaper reagents on the reaction and improving the yield.
• the present invention provides a new method for preparing an intermediate of dipeptidyl peptidase-IV inhibitor represented by Chemical Formula 2, the method comprising:
• Step a preparing a compound represented by Chemical Formula 6 by ring-opening of epoxide ring using Grinard reagent in a compound represented by Chemical Formula 5;
• Step b preparing a compound represented by Chemical Formula 7 by reacting the compound represented by Chemical Formula 6 with sodium azide;
• Step c preparing a compound represented by Chemical Formula 8 by reacting the compound represented by Chemical Formula 7 with triphenylphosphine;
• Step d preparing a compound represented by Chemical Formula 9 by ring-opening of aziridine ring using a cyanogen-based reagent in the compound represented by Chemical Formula 8; and
• Step e preparing a compound represented by Chemical Formula 2 by hydrolyzing the compound represented by Chemical Formula 9 using a base.
• a compound of Chemical Formula 6, which has been subjected to ring-opening of epoxide ring is prepared by reacting the compound represented by Chemical Formula 5 in Step a with a 2,4,5-trifluorophenyl magnesium bromide reagent in the presence of a copper (I) iodide catalyst.
• an azido compound represented by Chemical Formula 7 is prepared by reacting the compound represented by Chemical Formula 6 in Step b with sodium azide in the presence of a copper (I) iodide catalyst.
• triphenylphosphine is used in the compound represented by Chemical Formula 7 in Step c to prepare an aziridine ring compound, and then an amine-protecting group is introduced to prepare a compound represented by Chemical Formula 8.
• a compound represented by Chemical Formula 9 is prepared by reacting the compound represented by Chemical Formula 8 with a cyanogen-based reagent such as sodium cyanide, potassium cyanide, etc. under 18-crown-6 and ammonium chloride in Step d.
• a compound represented by Chemical Formula 2 is prepared by hydrolyzing the compound represented by Chemical Formula 9 with a base, and sodium hydroxide, potassium hydroxide, lithium hydroxide, etc. may be used as a preferable base.
• the present invention also provides a compound represented by the following Chemical Formula 8 or 9, wherein the compound is produced as an intermediate when producing the compound represented by Chemical Formula 2.
• the present invention provides a new method for preparing an intermediate of dipeptidyl peptidase-IV inhibitor represented by Chemical Formula 3, the method comprising:
• Step a′ preparing a compound represented by Chemical Formula 11 by introducing t-butoxy group to hydroxyl group of a compound represented by Chemical Formula 10; and (Step b′) preparing a compound represented by Chemical Formula 3 by inducing a cyclization by reacting the compound represented by Chemical Formula 11 with ethylene diamine.
• a compound represented by Chemical Formula 11 in which a hydroxyl group is substituted with a t-butyl group, is prepared by reacting a compound represented by Chemical Formula 10 with isobutyrene gas under an acid catalyst in Step a′.
• the compound represented by Chemical Formula 10 is commercially available or may be prepared by methods known in the art, and may be obtained by using sodium nitrite and potassium bromide from L-serine to replace an amine group with a bromine group, for example, by a method described in Tetrahedron Letter: Asymmetry 1994; 2517, and then reacting the resulting product with methanol under an acid catalyst such as thionyl chloride.
• a compound represented by Chemical Formula 3 is prepared by inducing a cyclization by reacting the compound represented by Chemical Formula 11 with ethylene diamine in the presence of a base in Step b′, and then sodium hydrogen carbonate, sodium carbonate, potassium carbonate, potassium carbonate, pyridine, triethylamine, etc. may be used as a preferable base.
• the present invention provides an improved method for preparing dipeptidyl peptidase-IV inhibitor represented by
• Chemical Formula 1 the method comprising: (Step 1) preparing a compound represented by Chemical Formula 4 by bonding a compound represented by Chemical Formula 2 and a compound represented by Chemical Formula 3 with peptide bond by reacting them using triphenylphosphine, bis(2,2′-benzothiazolyl)disulfide, and a base in the presence of a reaction solvent; and
• Step 2 preparing a compound represented by Chemical Formula 1 by removing an amine-protecting group of the compound -represented by Chemical Formula 4 produced in the above Step 1.
• Step 1 is a step of preparing a compound represented by Chemical Formula 4 by bonding a compound represented by Chemical Formula 2 and a compound represented by Chemical Formula 3 with peptide bond by reacting them using triphenylphosphine, bis(2,2′-benzothiazolyl)disulfide, and a base in the presence of a reaction solvent.
• toluene, tetrahydrofuran, methylene chloride, acetonitrile, N,N-dimethylformamide, etc. may be used as the reaction solvent.
• a tertiary amine such as N-methyl morpholine, isopropylethylamine, triethylamine, pyridine, etc. may be used as the base.
• the compound represented by Chemical Formula 2 or 3 is commercially available or may be prepared by using a known method or the method described in
• the reaction of the above Step 1 is performed at ⁇ 20° C. to 80° C., and there is a problem that the yield is reduced due to difficulties in performing the reaction when the temperature is out of the range.
• Step 2 is a step of preparing a compound represented by Chemical Formula 1 by removing an amine-protecting group of the compound represented by Chemical Formula 4 produced in the above Step 1.
• the removal of the protecting group in the Step 2 may be conducted under the acidic condition or through a hydrogen reaction.
• the amine-protecting group is butoxy carbonyl (Boc)
• the protecting group may be removed under the acidic condition, such as trifluoroacetic acid/dichloromethane, ethyl acetate/hydrogen chloride, diethyl ether/hydrogen chloride, hydrogen chloride/dichloromethane, or methanol/hydrogen chloride
• the amine-protecting group is benzyloxycarbonyl (Cbz)
• the protecting group may be removed through a hydrogen reaction in the presence of palladium/carbon.
• the dipeptidyl peptidase-IV inhibitor of the present invention represented by Chemical Formula 1, may be used in the form of a pharmaceutically acceptable salt, and an acid addition salt formed by a pharmaceutically acceptable free acid is useful as a salt.
• Inorganic and organic acids may be used as the free acid, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, etc.
• citric acid acetic acid, lactic acid, maleic acid, fumaric acid, gluconic acid, methanesulfonic acid, acetic acid, glycolic acid, succinic acid, tartaric acid, 4-toluenesulfonic acid, galacturonic acid, embonic acid, glutamic acid, or aspartic acid
• organic acid Preferably, hydrochloric acid may be used as the inorganic acid, and tartric acid may be used as the organic acid.
• the acid addition salt according to the present invention may be prepared by a typical method, and may be prepared, for example, by dissolving a compound represented by Chemical Formula in a water-miscible organic solvent, for example, acetone, methanol, ethanol, or acetonitrile and adding an excess of an organic acid thereto, or by adding an acid aqueous solution of an inorganic acid thereto and then precipitating or crystallizing it. Subsequently, a preparation may be performed by evaporating the solvent or an excess of the acid from this mixture and then drying it to obtain an addition salt or suction-filtrate a precipitated salt.
• a water-miscible organic solvent for example, acetone, methanol, ethanol, or acetonitrile
• a preparation may be performed by evaporating the solvent or an excess of the acid from this mixture and then drying it to obtain an addition salt or suction-filtrate a precipitated salt.
• a preparation method according to the present invention may reduce costs in preparing a compound of Chemical Formula 1 by using low-priced bis(2,2′-benzothiazolyl)disulfide, and may be useful for mass production due to an increase in its yield.
• Step a Preparation of (S)-1-chloro-3-(2,4,5-trifluorophenyl)propane-2-ol (Chemical Formula 6)
• Step b Preparation of (S)-1-azido-3-(2,4,5-trifluorophenyl)propane-2-ol (Chemical Formula 7)
• Step c Preparation of (R)-N-amine-protecting group 2-(2,4,5-trifluorobenzyl)aziridine (Chemical Formula 8)
• reaction solution was cooled to room temperature; 5.35 g of N,N-diisopropylethylamine, 0.43 g of 4-dimethylaminopyridine, and 3.0 g of acetylchloride were added to the cooled reaction solution; and then the resulting reaction solution was stirred for 2 hours. After completing the reaction, 0.4 g of hydrogen peroxide was added; and the resulting reaction solution was stirred for 1 hour and then concentrated under reduced pressure. 40 mL of n-hexane was added to the concentrated residue; and the resulting concentrated reside was stirred for 1 hour. The resulting solid was filtered out and the filtrate was concentrated under reduced pressure. The residue was purified with column chromatography to obtain 4.74 g of a title compound.
• reaction solution was cooled to room temperature; 5.35 g of N,N-diisopropylethylamine, 0.43 g of 4-dimethylaminopyridine, and 5.34 g of benzoylchloride were added to the cooled reaction solution; and then the resulting reaction solution was stirred for 2 hours. After completing the reaction, 0.4 g of hydrogen peroxide was added; and the resulting reaction solution was stirred for 1 hour and then concentrated under reduced pressure. 40 mL of n-hexane was added to the concentrated residue; and the resulting concentrated reside was stirred for 1 hour. The resulting solid was filtered out and the filtrate was concentrated under reduced pressure. The residue was purified with column chromatography to obtain 7.03 g of a title compound.
• reaction solution was cooled to room temperature; 5.35 g of N,N-diisopropylethylamine, 0.43 g of 4-dimethylaminopyridine, and 12.81 g of 9-fluoreneylmethoxycarbonylchloride were added to the cooled reaction solution; and then the resulting reaction solution was stirred for 2 hours. After completing the reaction, 0.4 g of hydrogen peroxide was added; and the resulting reaction solution was stirred for 1 hour and then concentrated under reduced pressure. 40 mL of n-hexane was added to the concentrated residue; and the resulting concentrated reside was stirred for 1 hour. The resulting solid was filtered out and the filtrate was concentrated under reduced pressure. The residue was purified with column chromatography to obtain 10.03 g of a title compound.
• reaction solution was cooled to 0-5° C.; 5.35 g of N,N-diisopropylethylamine and 7.24 g of tosylchloride were added to the cooled reaction solution; the resulting reaction solution was stirred for 2 hours; and then concentrated under reduced pressure. 40 mL of isopropylether was added to the concentrated residue and then the resulting concentrated reside was stirred for 1 hour. The resulting solid was filtered out and the filtrate was concentrated under reduced pressure. The residue was purified with column chromatography to obtain 7.07 g of a title compound.
• Step d Preparation of (R)-N-amine-protecting group 2-(2,4,5-trifluorobenzyl)aziridine (Chemical Formula 9)
• Step e Preparation of (R)-3-amine-protecting group-amino-4-(2,4,5-trifluorophenyl)butanoic acid (Chemical Formula 2)
• the reaction solution was stirred for 12 hours, and then concentrated under reduced pressure.
• Step b′ Preparation of (R)-3-(t-butoxymethyl)piperazine-2-one (Chemical Formula 3)
• Step 1 Preparation of t-butyl (R)-4-[(R)-2-(t-butoxymethyl)-3-oxopiperazine-1-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butane-2-ylcarbamate (Chemical Formula 4)
• reaction solution was cooled to 0° C, and then a solution prepared by dissolving 5.6 g of (R)-3-(t-butoxymethyl)piperazine-2-one (Chemical Formula 3) produced in the above Example 2 to 40 mL of toluene, and 2.4 mL of pyridine were slowly added. After 30 minutes, the temperature of the reaction solution was increased to room temperature, and then stirred for further 1 hour. pH of the reaction solution was adjusted to 2.5 using saturated citric acid aqueous solution, and then diluted with 400 mL of ethyl acetate. The reaction solution was washed with brine in twice, and an organic layer was dehydration-concentrated with magnesium sulfate. A residue was purified with column chromatography to obtain 838 mg of a title compound.
• Step 1 Preparation of (R)-4-[(R)-3-amino-4-(2,4,5-trifluorophenyl) butanoyl]-3-(t-butoxymethyl)piperazine-2-one (Chemical Formula 1)
• Step 2 Preparation of (R)-4-[(R)-3-amino-4-(2,4,5-trifluorophenyl) butanoyl]-3-(t-butoxymethyl)piperazine-2-one (Chemical Formula 1) tartrate
• Step 1 55 mg of the compound produced in the above Step 1 was dissolved in 0.56 mL of acetone; a solution prepared by dissolving 26 mg of L-tartaric acid to 0.35 mL of ethanol/water [9/1(v/v)] was slowly added; and then stirred for 30 minutes. 0.56 mL of 2-propanol was again added thereto, and stirred for 10 minutes to obtain 77 mg of a title compound as a solid.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Diabetes (AREA)
• General Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicinal Chemistry (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Child & Adolescent Psychology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)
• Enzymes And Modification Thereof (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=42828845

Family Applications (2)

Family Applications After (1)

Country Status (17)

Cited By (1)

Families Citing this family (5)

Citations (2)

Family Cites Families (21)

• 2010
  • 2010-03-30 US US13/259,699 patent/US20120016125A1/en not_active Abandoned
  • 2010-03-30 PL PL10759016T patent/PL2415753T3/pl unknown
  • 2010-03-30 BR BRPI1014087-5A patent/BRPI1014087B1/pt active IP Right Grant
  • 2010-03-30 EP EP10759016.8A patent/EP2415753B1/en active Active
  • 2010-03-30 MX MX2011010204A patent/MX2011010204A/es active IP Right Grant
  • 2010-03-30 CN CN201080015010.2A patent/CN102378751B/zh active Active
  • 2010-03-30 AU AU2010232085A patent/AU2010232085B2/en active Active
  • 2010-03-30 CA CA2800245A patent/CA2800245C/en active Active
  • 2010-03-30 ES ES10759016.8T patent/ES2523995T3/es active Active
  • 2010-03-30 RU RU2011141208/04A patent/RU2499792C2/ru active
  • 2010-03-30 WO PCT/KR2010/001947 patent/WO2010114291A2/ko active Application Filing
  • 2010-03-30 JP JP2012503324A patent/JP5475863B2/ja active Active
  • 2010-03-30 NZ NZ595542A patent/NZ595542A/xx unknown
  • 2010-03-30 EP EP13175341.0A patent/EP2669265A3/en not_active Withdrawn
  • 2010-03-30 CN CN201410104035.XA patent/CN103922971B/zh active Active
  • 2010-03-30 MX MX2012015019A patent/MX344498B/es unknown
  • 2010-03-30 SG SG2011070919A patent/SG174974A1/en unknown
  • 2010-03-30 CA CA2756893A patent/CA2756893C/en active Active
  • 2010-03-30 NZ NZ608028A patent/NZ608028A/en unknown
  • 2010-03-30 KR KR1020100028477A patent/KR101152899B1/ko active Protection Beyond IP Right Term
• 2011
  • 2011-09-21 IL IL215290A patent/IL215290A/en active IP Right Grant
• 2012
  • 2012-09-10 HK HK12108817.0A patent/HK1168085A1/xx unknown
• 2014
  • 2014-09-02 IL IL234436A patent/IL234436A/en active IP Right Grant
  • 2014-10-03 US US14/506,025 patent/US9249109B2/en active Active

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events